VIDAMAS AND THERMAL THERAPY
Thermal therapy is a well-recognized treatment for cancer and has been officially approved in most countries including, America, Germany, France, Italy, Great Britain, Canada, Japan.
Thermal treatment can be in the form of applied heat or cold (cryoablation). As for heating, when a cancerous cell reaches a temperature of about 43⁰Celsius the cell dies.
Historically, there are two forms of hyperthermia treatment:
- Whole body hyperthermia involves raising the temperature not just of the tumor but of the entire body and must be tightly controlled and monitored to avoid substantial collateral damage.
- Targeted hyperthermia uses heated probes inserted into or in proximity to the tumor. The limitation being that heat, as radiant energy, will spread out in all directions from the source point until dissipated. If the heat is too low it will be ineffective, if the heat is too high it will cause collateral damage.
For hyperthermia in these two modalities the problem is the focus of the energy and the fact that the available energy dissipates based on distance from source to object not in a linear fashion but as a factor of the square of that distance. A small increase in distance can make a huge difference in energy loss.
For the thermal approaches, the efficiency is also diminished by the fact that cells are protected against temperature changes by having a cell wall which is itself a thermal barrier. Applying heat to the outside of a cell is a very inefficient way to heat the inside of the cell.
This basic problem in the use of hyperthermia gave rise to a great deal of research in many countries to find a way to selectively heat cancerous cells to the point of cell death with a highly focused energy form that does not harm normal cells.
In the report published in Chicago USA in 1979, using pulsed magnetic fields, the remission rate found in subjects was 86%. (Gordon RT, et al., Cellular Hyperthermia. A biophysical approach to cancer treatment via intracellular temperature and biophysical alterations. Med Hypotheses. 1979 Jan;5(1):83-102. PMID: 459972; UI: 79220965.)
In the report published by the University of Tokyo in 2017, also using pulsed magnetic fields, the remission rate observed was 96%.
However, these results were found in very small animals. In both cases the limiting factor was the scale of the device. The 1979 device was composed of a pulsed electromagnet coil. With a power supply at 30,000 Watts it provided a rapid (20 minute) treatment but the size of the ring into which the subject was placed was maximized at about 12 cm diameter. Too small for any human patient
The Japanese trial in 2017 used a device in which the long axis of the permanent magnetic field was placed parallel to the cancerous lesion so that the lesion was within 10-15 mm of the magnet. This then limited the application to skin or superficial lesions. (Takeshi Kobayashi: Intracellular Hyperthermia Using Magnetic Nanoparticles: A Novel Method for Hyperthermia Clinical Applications. http://www.isc.chubu.ac.jp/istr/pdf/vol22/22-07.pdf )
The VIDAMAS device uses a complex array of permanent magnets interacting with an electromagnet at very low power (less than 6 Watts) but with the significant advantage of having an effective range to target of 150 mm.
With this range to target, the VIDAMAS 400 can reach a tumor anywhere in a normal sized adult body.
Moreover, the VIDAMAS treatment is:
- Without side effects
- Without aftereffects
Vidamas does not itself provide treatment but has made arrangements with various clinics and hospitals for the Vidamas Therapy to be available there.